Skip to main content
Submitted by Liyin Qiao on

Percutaneous Nephrolithotomy (PCNL) is a complicated process of removing large or complex kidney stones and typically carried out by senior surgeons. With the Percutaneous Access to Kidney Assist Device (PAKAD), an innovation developed by the team at the Institute of Technical Education (ITE), the surgery is set to become simpler, safer and shorter. The device uses precision engineering mechanisms to align the needle with the target, ensuring higher accuracy and reducing the risk of surgery complications and recovery periods.

ITE first demonstrated the PAKAD prototype at TechInnovation, IPI’s flagship technology-industry brokerage event in 2013. HCMT Holdings Pte Ltd (HCMT) was keen to pursue a joint collaboration to further develop and commercialise the device. Through Invivo Medical Pte Ltd, a start-up funded by HCMT, PAKAD will be commercialised and a licensing agreement was signed between Invivo, ITE, National University Hospital (NUH) and National University of Singapore (NUS) on 29 August 2017. PAKAD is expected to reach the market by Q2 of 2019.

“This is an excellent example of industry-institution partnership to develop innovative and integrated solutions to improve productivity and processes. We are grateful to NUH, NUS and Invivo Medical, to enable ITE to create and patent the PAKAD for safe kidney surgery,” said Ms Low Khah Gek, CEO, ITE.

“The route to commercialising innovation can be a long one. We are delighted that the technology match that stemmed from TechInnovation four years ago has come to fruition and will be available in the market in the near future. The success of this collaboration is underpinned by the unique expertise each partner brings and their shared commitment to bring this innovation to market,” said Dr Sze Tiam Lin, Senior Director, IPI.

Sub Title
A new precision-engineered device developed by ITE and commercialised through industry collaboration is set to make complex kidney stone removal surgeries safer, faster, and more accessible.
Impact Title
Transforming Kidney Stone Surgery with Innovation
Sub Title
Transforming Kidney Stone Surgery with Innovation
Legacy ID
59047
Sub Heading
A breakthrough device simplifies and improves kidney stone surgery.
At a glance
HCMT Holdings Pte Ltd / Invivo Medical Pte Ltd
Client
Health & Personal Care
Industry
TechInnovation, Technology Matching
IPI Service
Percutaneous Access to Kidney Assist Device (PAKAD)
Key Technology
Add Impact
The PAKAD device introduces a new level of precision to kidney stone removal surgeries, reducing the risk of complications and shortening patient recovery times. By making the procedure simpler and safer, it enables more surgeons to perform PCNL, increasing accessibility for patients.
Enhanced Surgical Safety and Efficiency
The partnership between ITE, HCMT Holdings, Invivo Medical, NUH, and NUS, facilitated by IPI Singapore, demonstrates the power of cross-sector collaboration in accelerating medical innovation from prototype to commercial product. The licensing agreement and impending market launch highlight the effectiveness of this collaborative approach.
Successful Industry-Institution Collaboration
Glance Title
At a Glance
Sub Title
A multi-institutional partnership, catalysed by IPI Singapore, enabled the commercialisation of a precision device that makes kidney stone surgery safer and more efficient.
How it happened
The journey began with ITE showcasing the PAKAD prototype at TechInnovation 2013, where HCMT Holdings expressed interest in collaboration. This initial connection, facilitated by IPI Singapore, led to a joint development and commercialisation effort involving Invivo Medical, ITE, NUH, and NUS. After four years of partnership and refinement, a licensing agreement was signed in August 2017, paving the way for the device’s market launch.
The challenge
PCNL surgeries are highly complex and require significant expertise, limiting the number of surgeons able to perform them and increasing the risk of complications for patients.
Complexity of Traditional Procedures
The technical demands and risks associated with traditional PCNL procedures have restricted their accessibility, underscoring the need for innovative solutions that can simplify the process and improve outcomes.
Barriers to Widespread Adoption
The challenges title
The Challenge
The challenges description

Percutaneous Nephrolithotomy (PCNL) is a complex surgical procedure used to remove large or intricate kidney stones. Traditionally, this operation is technically demanding and typically performed only by highly experienced senior surgeons. The process involves precise alignment and access to the kidney, which poses significant risks if not executed accurately. The inherent complexity of PCNL increases the likelihood of surgical complications, prolongs recovery periods for patients, and limits the procedure’s accessibility to only a select group of skilled practitioners. These challenges highlight the need for a solution that can simplify the process, improve surgical accuracy, and reduce the risks and recovery time associated with kidney stone removal.

The Solution Title
The Solution
The Solution Description

IPI Singapore facilitated the connection between the Institute of Technical Education (ITE) and HCMT Holdings Pte Ltd at TechInnovation, its flagship technology-industry brokerage event, enabling a joint collaboration to further develop and commercialise the Percutaneous Access to Kidney Assist Device (PAKAD). By providing a platform for technology matching and partnership formation, IPI played a pivotal role in advancing the commercialisation journey of this innovative medical device. The PAKAD, developed by ITE, leverages precision engineering mechanisms to align the surgical needle with the target kidney stone, ensuring higher accuracy during PCNL procedures. This innovation reduces the risk of surgical complications and shortens patient recovery periods. Through Invivo Medical Pte Ltd, a start-up funded by HCMT, the device is being commercialised, with a licensing agreement signed between Invivo, ITE, National University Hospital (NUH), and National University of Singapore (NUS). PAKAD is expected to be available in the market by Q2 of 2019, making safer and more efficient kidney stone removal accessible to more patients.

Testimonial Section
Testimonial title
Institution Perspective
Testimonial description

"This is an excellent example of industry-institution partnership to develop innovative and integrated solutions to improve productivity and processes. We are grateful to NUH, NUS and Invivo Medical, to enable ITE to create and patent the PAKAD for safe kidney surgery."

Testimonial Name
Ms Low Khah Gek
Testimonial Designation
CEO, ITE
Testimonial title
IPI Perspective
Testimonial description

"The route to commercialising innovation can be a long one. We are delighted that the technology match that stemmed from TechInnovation four years ago has come to fruition and will be available in the market in the near future. The success of this collaboration is underpinned by the unique expertise each partner brings and their shared commitment to bring this innovation to market."

Testimonial Name
Dr Sze Tiam Lin
Testimonial Designation
Senior Director, IPI
Business impact Heading
Business Impact
Business impact title
Accelerating Medical Innovation to Market
Impact scores
Counter Text
Institutions Partnered
Total count
4
Counter Text
Years to Commercialisation
Total count
4
Counter Text
Expected Market Launch
Total count
2019
Overview

HCMT Holdings Pte Ltd (HCMT) is a healthcare company committed to advancing medical technologies. Through its funded start-up, Invivo Medical Pte Ltd, HCMT collaborates with leading institutions to bring innovative healthcare solutions to market.

Data source
prod
Area Of interest
Slug
innovation-makes-kidney-stone-removal-procedure-simpler-shorter-and-safer